Moderna (MRNA) to Supply an 20M Doses of COVID-19 Vaccine to COVAX for 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
December 10, 2021 9:00 AM ESTTotal of 54 million doses to be supplied to COVAX in 2021
New 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of 136.5 million doses; Gavi retains option for additional 30 million in Q2 and 100 million in Q3 2022
Gavi now retains the option to procure a total of up to 650 million doses in 2021 and 2022
CAMBRIDGE, Mass.--(BUSINESS... More
